License Type: (?)






  1. American Medical Systems Holdings, Inc.
  2. C.R. Bard, Inc.
  3. B-K Medical APS/Analogic Corporation
  4. Boston Scientific Corporation
  5. GE Healthcare/General Electric Company
  6. Hitachi Medical Systems America, Inc./Hitachi LTD
  7. Johnson & Johnson
  8. Pfizer, Inc.
  9. Royal Philips Electronics NV
  10. Siemens AG
Market Reports


WOMEN'S HEALTH: U.S. MARKETS FOR URINARY INCONTINENCE MANAGEMENT PRODUCTS


153 Pages | 35 Exhibits | 2008 Analysis | Forecasts Through 2010




Enter a search phrase to search within this report:

Get the full unredacted version of this report by purchasing today.





Urinary incontinence affects more than 15 million people in the U.S.; of these, an estimated 85% are women. The most prevalent types of incontinence are stress, urge, mixed, and overflow incontinence. In 2007, U.S. sales of incontinence products (including drugs and diagnostic and therapeutic products) totaled approximately $1.9 billion, with drugs accounting for 75% of sales, therapeutic products accounting for 16% of sales, and diagnostic products accounting for the remaining 9% of sales. Over the forecast period covered by this report, total sales are expected to increase at a compound annual rate of 7.7%, reaching approximately $2.4 billion in the year 2010.

This new Medtech Insight report by Elsevier BV/Reed Elsevier Group PLC presents a detailed overview of the U.S. urinary incontinence management products market. Major topics covered by this report include types and causes of incontinence, diagnostic products (e.g., urodynamic studies systems and office-based ultrasound systems), therapeutic products (e.g., stress urinary incontinence surgery products such as pubovaginal slings, tension-free vaginal tape, and bone anchors; urethral prostheses and inserts; bulking agents; pelvic exercisers such as pelvic nerve stimulators and behavioral therapy products such as biofeedback devices and vaginal cones; and sacral nerve stimulators), and an analysis of each product market.



EXECUTIVE SUMMARY

i.       Urinary Incontinence Management

a.     Types and Causes

b.     Patient Volumes

c.       Diagnosis

i.       Urodynamic Studies Products

ii.       Office-Based Ultrasound Systems

d.     Treatment

i.       Stress Urinary Incontinence Surgery Products

ii.       Urethral Prostheses and Inserts

iii.     Bulking Agents

iv.     Pelvic Exercisers

v.     Sacral Nerve Stimulators

vi.     Incontinence Pharmaceuticals

e.     Combined Market Analysis

 

Exhibit ES-1:       Types of Urinary Incontinence

Exhibit ES-2:       Female Incontinence, Patient Volumes Forecast, 2005-2010

Exhibit ES-3:       Urinary Incontinence Management Products, Combined Market Forecast, 2005-2010

 

1.  URINARY INCONTINENCE MANAGEMENT PRODUCTS

1.1 Types and Causes

1.1.1 Stress Urinary Incontinence

1.1.2 Urge Incontinence

1.1.3 Mixed Incontinence

1.1.4 Overflow Incontinence

1.1.5 Other Types of Incontinence

1.2 Providers and Treatment Sites

1.3 Patient Volumes

1.4 Diagnosis

1.4.1 Basic Evaluation

1.4.1.1 Patient History

1.4.1.2 Physical Examination

1.4.1.3 Post-Void Residual Volume

1.4.1.4 Urinalysis

1.4.1.5 Other Tests

1.4.1.6 Treatment Selection

1.4.2 Specialized Tests

1.4.2.1 Urodynamic Studies

1.4.2.1.1 Equipment and Suppliers

1.4.2.1.2 Procedures

1.4.2.2 Cystoscopy/Cystourethroscopy

1.4.2.2.1 Equipment and Suppliers

1.4.2.2.2 Procedures

1.4.2.3 Imaging

1.4.2.3.1 Equipment and Suppliers

1.4.2.3.2 Procedures

1.5 Treatment

1.5.1 Behavioral Therapy

1.5.1.1 Bladder Training

1.5.1.2 Pelvic Muscle Rehabilitation

1.5.1.2.1 Pelvic Muscle Exercises

1.5.1.2.2 Biofeedback

1.5.1.2.3 Vaginal Weight Training

1.5.1.2.4 Pelvic Floor Stimulation

1.5.2 Incontinence Therapy Systems

1.5.3 Drug Therapy

1.5.3.1 Urge Incontinence Drugs

1.5.3.1.1 Anticholinergic Agents

1.5.3.1.1.1 Detrol

1.5.3.1.1.2 Ditropan

1.5.3.1.1.3 Enablex

1.5.3.1.1.4 OXYTROL

1.5.3.1.1.5 SANCTURA

1.5.3.1.1.6 VESIcare

1.5.3.1.2 Tricyclic Agents

1.5.3.1.3 Calcium Channel Blockers

1.5.3.2 Stress Urinary Incontinence Drugs

1.5.3.2.1 Alpha-Adrenergic Agonists

1.5.3.2.2 Estrogen

1.5.3.2.3 Yentreve

1.5.3.3 Overflow Incontinence Drugs

1.5.3.4 Products in Development

1.5.3.4.1 Botulinum Toxin

1.5.3.4.2 Capsaicin

1.5.3.4.3 Fesoterodine

1.5.3.4.4 Other Approaches

1.5.4 Surgical Therapy

1.5.4.1 Bladder Neck Hypermobility Treatment

1.5.4.1.1 Retropubic Urethropexy

1.5.4.1.2 Transvaginal Needle Bladder Neck Suspension

1.5.4.1.3 Anterior Vaginal and Abdominal Paravaginal Repairs

1.5.4.2 Intrinsic Sphincter Deficiency Treatment

1.5.4.2.1 Sling Procedures

1.5.4.2.2 Tension-Free Vaginal Tape Procedures

1.5.4.2.3 Artificial Urinary Sphincters

1.5.4.3 Detrusor Instability Treatment

1.5.4.3.1 Augmentation Intestinocystoplasty

1.5.4.3.2 Urinary Diversion

1.5.4.4 Outlet Obstruction Treatment

1.5.4.5 Surgery Enhancement Products

1.5.4.5.1 Bone Anchor Systems

1.5.4.5.2 Pubovaginal Slings

1.5.5 Periurethral Bulking Treatment

1.5.6 Urethral Prostheses and Inserts

1.5.7 Sacral Nerve Stimulators

1.5.8 Collagen Remodeling Systems

1.5.8.1 Renessa

1.5.8.2 SURx

1.6 Market Analysis

1.6.1 Combined Market Analysis

1.6.2 Diagnostic Incontinence Products

1.6.2.1 Urodynamic Studies Products

1.6.2.2 Office-Based Ultrasound Products

1.6.3 Therapeutic Incontinence Products

1.6.3.1 Stress Urinary Incontinence Surgery Products

1.6.3.2 Urethral Prostheses and Inserts

1.6.3.3 Bulking Agents

1.6.3.4 Pelvic Exerciser Products

1.6.3.5 Sacral Nerve Stimulation Products

1.6.4 Incontinence Pharmaceuticals

Exhibit 1-1:           The Female Urogenital System

Exhibit 1-2:           Types of Urinary Incontinence

Exhibit 1-3:           2008, Stress Urinary Incontinence Classification System

Exhibit 1-4:           2008, Drugs That May Influence Bladder Function

Exhibit 1-5:           Female Incontinence, Patient Volumes Forecast, 2005-2010

Exhibit 1-6:           2008, Urodynamic Tests and Applications

Exhibit 1-7:           2008, Selected Office-Based Urodynamic Systems

Exhibit 1-8:           Urodynamic Studies, Procedure Volumes Forecast, 2005-2010

Exhibit 1-9:           2008, Selected Office-Based Diagnostic Ultrasound Scanners

Exhibit 1-10:       Office-Based Ultrasound for Urologic Evaluation, Procedure Volumes Forecast, 2005-2010

Exhibit 1-11:       2008, Treatment Options for Urinary Incontinence

Exhibit 1-12:       Stress Urinary Incontinence Treatment, Procedure Volumes Forecast, 2005-2010

Exhibit 1-13:       Urge Incontinence Treatment, Procedure Volumes Forecast, 2005-2010

Exhibit 1-14:       2008, Selected Behavioral Therapy Products for Incontinence Treatment

Exhibit 1-15:       2008, Selected Developments in Incontinence Drug Therapy

Exhibit 1-16:       2008, Bladder Neck Hypermobility and Intrinsic Sphincter Deficiency, Surgical Treatment Options

Exhibit 1-17:       2008, Transvaginal Needle Suspension Treatments, by Type

Exhibit 1-18:       2008, Selected Pubovaginal Slings

Exhibit 1-19:       2008, Selected Bulking Agents

Exhibit 1-20:       2008, Selected Sacral Nerve Stimulators

Exhibit 1-21:       Urinary Incontinence Management Products, Combined Market Forecast, 2005-2010

Exhibit 1-22:       Urodynamic Studies Products, Market Forecast, 2005-2010

Exhibit 1-23:       Office-Based Ultrasound Systems, Market Forecast, 2005-2010

Exhibit 1-24:       2007, Office-Based Ultrasound Systems Market, Share by Supplier

Exhibit 1-25:       Stress Urinary Incontinence Surgery Products, Market Forecast, 2005-2010

Exhibit 1-26:       Urethral Prostheses and Inserts, Market Forecast, 2005-2010

Exhibit 1-27:       Bulking Agents, Market Forecast, 2005-2010

Exhibit 1-28:       2007, Bulking Agents Market, Share by Supplier

Exhibit 1-29:       Pelvic Exerciser Products, Market Forecast, 2005-2010

Exhibit 1-30:       Sacral Nerve Stimulation Products, Market Forecast, 2005-2010

Exhibit 1-31:       Incontinence Pharmaceuticals, Market Forecast, 2005-2010

Exhibit 1-32:       2007, Incontinence Pharmaceuticals Market, Share by Supplier

 

2.           COMPANY PROFILES

2.1       American Medical Systems Holdings, Inc.

2.2       C.R. Bard, Inc.

2.3       B-K Medical APS/Analogic Corporation

2.4             Boston Scientific Corporation

2.5       GE Healthcare/General Electric Company

2.6       Hitachi Medical Systems America, Inc./Hitachi LTD

2.7       Johnson & Johnson

2.8       Pfizer, Inc.

2.9       Royal Philips Electronics NV

2.10   Siemens AG

 

APPENDIX:   COMPANY LISTING

Published by Medtech Insight and distributed exclusively by LSI



This report is listed in the following markets:
Drug Delivery, Gynecology and Urology